-
Price Momentum
MRNA is trading near the bottom of its 52-week range and below its 200-day simple moving average.
-
Price change
The price of MRNA shares has decreased $0.61 since the market last closed. This is a 2.28% drop.
-
Opened at $26.21.
The stock opened $0.53 lower than its previous close.
Key terms
About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
-
Market cap: $10.44B
A market capitalization between $10 billion and $200 billion places MRNA in the large capitalization category.
Key terms
Smart score
Latest MRNA news
MRNA Financials
-
Total revenue: $3.24B (1Y), $142.00M (Q2)
Total Revenue decreased 52.69% since last year and increased 31.48% since last quarter.
-
Net income: -$3.56B (1Y), -$825.00M (Q2)
Net Income increased 24.46% since last year and increased 15.04% since last quarter.
-
Earnings per share: -$9.27 (1Y), -$2.13 (Q2)
EPS increased 24.85% since last year and increased 15.47% since last quarter.
Key terms
MRNA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MRNA Competitors
-
How competitors are chosen
MRNA's competitors are included in the Health Technology sector and Biotechnology group
-
Market cap: $10.44B
A market capitalization between $10 billion and $200 billion places MRNA in the large capitalization category.
Key terms
Latest investing news
-
Silver prices hit record high as investors rush into safe havens
-
Jamie Dimon announces massive $10 billion bet on US national security: ‘We need to act now’
-
Dow tumbles nearly 900 points after Trump reignites trade war between the world’s two largest economies
-
Jamie Dimon is worried about a stock market correction